专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110207119A1 METHODS FOR PREDICTING A CANCER PATIENT'S RESPONSE TO SUNITINIB 审中-公开
标题翻译：预防癌症患者对SUNITINIB的反应的方法
公开(公告)号：US20110207119A1
公开(公告)日：2011-08-25
申请号：US13029895
申请日：2011-02-17
申请人： Sarah L. Suchy , Lauren M. Hancher , Stacey L. Brower
发明人： Sarah L. Suchy , Lauren M. Hancher , Stacey L. Brower
IPC分类号： C12Q1/68 , C12Q1/02
CPC分类号： G01N33/5011
摘要： The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to sunitinib prior to treatment. The method comprises expanding malignant cells in culture from a patient's tumor specimen, contacting the cultured cells with one or more active agents including sunitinib, and evaluating or quantifying the response to the active agent(s). The result of the assay is a dose response curve, which may be evaluated using algorithms described herein, so as to quantitatively assess drug sensitivity. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving sunitinib during chemotherapeutic treatment, in the course of standardized or individualized chemotherapeutic regimen.
摘要翻译：本发明提供了用于个体化癌症治疗化疗的方法，特别是用于评估患者在治疗前对舒尼替尼的反应性。该方法包括从患者肿瘤标本中扩增培养物中的恶性细胞，使培养的细胞与一种或多种活性剂（包括舒尼替尼）接触，并评估或定量对活性剂的反应。测定的结果是剂量反应曲线，其可以使用本文所述的算法进行评估，以便定量评估药物敏感性。通过本发明的方法确定的药物的体外应答与在化学治疗期间在标准化或个体化化学治疗方案中接受舒尼替尼时的患者的体内反应相关。

2. 发明申请

US20100311084A1 METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS 审中-公开
标题翻译：方法预防患者对EGFR抑制剂的反应
公开(公告)号：US20100311084A1
公开(公告)日：2010-12-09
申请号：US12795286
申请日：2010-06-07
申请人： Stacey Brower , Shara D. Rice , Theresa R. Cassino , Lahari Sakhamuri , Heather M. Buechel , Lauren M. Hancher
发明人： Stacey Brower , Shara D. Rice , Theresa R. Cassino , Lahari Sakhamuri , Heather M. Buechel , Lauren M. Hancher
IPC分类号： G01N33/574
CPC分类号： G01N33/5091 , G01N33/574 , G01N2333/485 , G01N2800/52
摘要： The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to a monoclonal EGFR antibody, such as cetuximab. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with a monoclonal EGFR antibody that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the monoclonal EGFR antibody during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen).
摘要翻译：本发明提供了用于个体化癌症治疗化学疗法的方法，特别是用于评估患者在用这些药物治疗之前对一种或多种表皮生长因子受体（EGFR）抑制剂的反应性。特别地，本发明提供了用于预测患者对单克隆EGFR抗体如西妥昔单抗的应答的体外化学应答测定。该方法通常包括从患者标本（例如活检标本）培养恶性细胞，使培养的细胞与作为患者候选治疗的单克隆EGFR抗体接触，并评价培养细胞对药物的应答。在某些实施方案中，从通过切割肿瘤组织制备的外植体培养恶性细胞的单层，并将单层细胞悬浮并铺板以进行化学敏感性测试。通过本发明的方法确定的对药物的体外应答与在化疗期间接受单克隆EGFR抗体（例如，与其他标准化或个体化化学治疗方案组合）时患者体内应答相关。

3. 发明申请

US20090286276A1 METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS 审中-公开
标题翻译：方法预防患者对EGFR抑制剂的反应
公开(公告)号：US20090286276A1
公开(公告)日：2009-11-19
申请号：US12466129
申请日：2009-05-14
申请人： Stacey L. BROWER , Shara D. RICE , Heather M. BUECHEL , Lauren M. HANCHER
发明人： Stacey L. BROWER , Shara D. RICE , Heather M. BUECHEL , Lauren M. HANCHER
IPC分类号： C12Q1/02
CPC分类号： G01N33/574 , G01N33/5011 , G01N2333/485 , G01N2800/52
摘要： The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an EGFR inhibitor, such as an EGFR tyrosine kinase inhibitor or a molecule targeting the extracellular domain of EGFR. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with an EGFR inhibitor that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the EGFR inhibitor during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen).
摘要翻译：本发明提供了用于个体化癌症治疗化学疗法的方法，特别是用于评估患者在用这些药物治疗之前对一种或多种表皮生长因子受体（EGFR）抑制剂的反应性。特别地，本发明提供了用于预测患者对EGFR抑制剂（例如EGFR酪氨酸激酶抑制剂或靶向EGFR细胞外结构域的分子）的反应的体外化学应答测定。该方法通常包括从患者标本（例如活检标本）培养恶性细胞，使培养的细胞与作为患者候选治疗的EGFR抑制剂接触，并评价培养细胞对药物的应答。在某些实施方案中，从通过切割肿瘤组织制备的外植体培养恶性细胞的单层，并将单层细胞悬浮并铺板以进行化学敏感性测试。通过本发明的方法确定的药物的体外应答与在化疗期间接受EGFR抑制剂（例如，与其他标准化或个体化化学治疗方案组合）时患者的体内反应相关。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式